Dr Daniel S. Olsson

Global Development Medical Director at AstraZeneca and Professor (adj) in Endocrinology at University of Gothenburg, Sweden.

[Dr Daniel S. Olsson @olsson_dr]

Wonderful to be back at ENDO. Great place to share cutting edge science. Presented our latest data yesterday. Also attended my last Reseach Affairs Core Committee meeting. Have been a great experience to serve on RACC. @TheEndoSociety

[Dr Daniel S. Olsson @olsson_dr]

Honored to see the big collaborative effort published in @TheLancetEndo

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Online—Risk and determinants of low and very low #bone mineral density and #fractures in a national cohort of Dutch adult #childhood #cancer #survivors (DCCSS-LATER): a cross-sectional study https://t.co/y6NcIpnmpx #BMD #osteoporosis #ChildhoodCancer #ASH2022

[Dr Daniel S. Olsson @olsson_dr]

Proud to see our latest research in @JAMANetworkOpen. The last decades' improved outcome for pediatric ALL pats have been accompanied with similar improvements for the general population, resulting in no clear relative survival gain. Emphasizing the need for relative comparisons.

[JAMA Network Open @JAMANetworkOpen]

The most common childhood cancer, acute lymphoblastic leukemia (ALL), has improved from 5% to 90% survival in the past 50 years. Despite this, patients with ALL still have high excess mortality compared to the general population in Sweden. https://t.co/x3oOCuy3dK

[Dr Daniel S. Olsson @olsson_dr]

Take a look at our new paper in JCEM that further our understanding about diabetes in patients with acromegaly. We show that concomitant diabetes in acromegaly is associated with an added mortality and morbidity risk https://t.co/2OIM0h1WzP #acromegaly #diabetes @EndoSocJournals

[Dr Daniel S. Olsson @olsson_dr]

So enormously proud of my first PhD student, Daniela Esposito, who yesterday brilliantly defended her thesis about Acromegaly. Prof Ferone did a wonderful job as opponent. A true international endocrine event! #acromegaly @ESEndocrinology

[Dr Daniel S. Olsson @olsson_dr]

@CoopmansEva @ESEndocrinology Likewise!

[Dr Daniel S. Olsson @olsson_dr]

First in a long time I have experienced being above the clouds. Thanks ECE2022 for a fantastic congress, full of impressive science and people. Already looking forward to next year! #ECE2022 @ESEndocrinology

[Dr Daniel S. Olsson @olsson_dr]

First F2F conference in too long time. Looking forward to see all at ECE2022 in Milan! @ESEndocrinology @cesarluizbogu @AlbertoMPereir1 #ECE2022

[Dr Daniel S. Olsson @olsson_dr]

Do DNA methylation pattern predict tumour progression in patients with nonfunctioning pituitary adenomas. We believe, Yes. See our newly published paper in JCEM. https://t.co/i95qUkt6Hw
#pituitary @EndoSocJournals @TheEndoSociety

[ESE_President @EsePresident]

I hope to see you all in #Milan for #ECE2022 - or online via ESE@Home! Connect, talk, support and be together #OurEndocrineCommunity #Inclusion #StrongerTogether

[Dr Daniel S. Olsson @olsson_dr]

Do not miss this interesting webinar from The Endocrine Society on the topic of Transitioning Careers: Industry and Academia. March 28, 1-2 PM ET. @TheEndoSociety #careerdevelopment Registration: https://t.co/Iutq7ubCVw

[Endocrine Society @TheEndoSociety]

Finding Your First Job as a Clinician | Join us for our Early Career SIG webinar on November 4 at 11:00 AM EDT. Enter a conversation touching on everything from elements of an effective interview to evaluating competing job offers. Register today: https://t.co/vHEf5gp07l

[European Society of Endocrinology (ESE) @ESEndocrinology]

Join @olsson_dr and Flavia Prodam at the next EYES Coffee Connections session, “Publish or perish - importance of research output”, on Friday 8 October. Register today. https://t.co/RgYh0sieiN

[European Society of Endocrinology (ESE) @ESEndocrinology]

Our next EYES Coffee Connections session, “Publish or perish - importance of research output” is taking place on Friday 8 October. Grab a coffee and join us for some light-hearted discussions. Register today. https://t.co/6nHTzSfjRh

[Dr Daniel S. Olsson @olsson_dr]

Proud to present a paper that further our understanding about one of the most important questions about acromegaly - Do acromegaly cause an excess incidence of tumours? #acromegaly #Cancer @PituitarySoc @TheEndoSociety @SahlgrenskaAcad https://t.co/5cOpzboBgI

[Dr Daniel S. Olsson @olsson_dr]

Great international collaboration resulting in new positive results for craniopharyngioma patients with hypothalamic #obesity - treated with bariatric surgery. https://t.co/aE0YRGMwgw @EndoSocJournals @TheEndoSociety @SahlgrenskaAcad

[Daniel J Drucker @DanielJDrucker]

Hypothalamic #obesity is challenging to manage-here #bariatricsurgery appears effective and relatively safe in the treatment of people with craniopharyngioma @EndoSocJournals https://t.co/aJCaVJFXQU

[European Society of Endocrinology (ESE) @ESEndocrinology]

New 2020 impact factors for Society journals are revealed! All journals continued to increase their scores, with @EJEndo receiving its highest ever impact factor of 6.664. Find out more https://t.co/Z8L0WG5Lk5
@EndoConnect @JMolEndo @EndoCancer

[Dr Daniel S. Olsson @olsson_dr]

Do not forget to apply for The Endocrine Society's Early Career Forum (deadline April 21). Wonderful opportunity to network and meet top endocrinology experts in small groups. @TheEndoSociety https://t.co/nTpk25qD0b

[European Society of Endocrinology (ESE) @ESEndocrinology]

Last chance to submit your cases for Clinical Update on Cushing’s Syndrome 2021! This is a great opportunity to discuss your cases with experts in the field. https://t.co/337Tv0Q8Hn